Potential alteration of tumor microenvironments by β-mercaptoethanol
1Altick Associates, 2000 Maxwell Drive, Suite 207, Hudson, WI 54016, USA.
Abstract:
The therapeutic effectiveness of immune checkpoint inhibitors in cancer patients is quite profound. However, it is generally accepted that further progress is curtailed by accompanying adverse events and by low cure rates linked to the tumor microenvironment. The multitudes of immune processes altered by low-molecular-weight thiols published over the past decades suggest they have potential to alter tumor microenvironment processes which could result in an increase in immune checkpoint inhibitor survival rates. Based on one of the most studied and most potent low-molecular-weight thiols, β-mercaptoethanol (BME), it is proposed that clinical assessment be undertaken to identify any BME benefits with relevance for proliferation/differentiation of immune cells, lymphocyte exhaustion, immunogenicity of tumor antigens and inactivation of suppressor cells/factors. The BME alterations projected to be most effective are: maintenance/replacement of glutathione in lymphocytes via facilitation of cysteine uptake, inhibition of suppressor cells/soluble factors and inactivation of free-radical, reactive oxygen species.
Insights
Low-molecular-weight thiols, like beta-mercaptoethanol (BME), may improve immune checkpoint inhibitor therapy by altering the tumor microenvironment. Clinical studies are proposed to assess BME
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Immune checkpoint inhibitors (ICIs) show profound therapeutic effects in cancer but face limitations due to adverse events and low cure rates.
- The tumor microenvironment (TME) significantly impacts ICI efficacy.
- Low-molecular-weight thiols are known to modulate immune processes and may offer a strategy to enhance ICI therapy by targeting the TME.
Purpose of the Study:
- To explore the potential of beta-mercaptoethanol (BME), a potent low-molecular-weight thiol, to improve cancer patient survival rates when used with ICIs.
- To investigate BME's effects on immune cell proliferation/differentiation, lymphocyte exhaustion, tumor antigen immunogenicity, and suppressor cell/factor inactivation within the TME.
Main Methods:
- Literature review on low-molecular-weight thiols and their immune-modulating properties.
- Proposed clinical assessment of BME's therapeutic benefits in cancer patients undergoing ICI therapy.
- Focus on BME's potential mechanisms: glutathione maintenance in lymphocytes, suppressor cell inhibition, and reactive oxygen species (ROS) inactivation.
Main Results:
- The study hypothesizes that BME can enhance ICI effectiveness through specific TME alterations.
- Projected effective BME alterations include facilitating cysteine uptake for glutathione replacement in lymphocytes.
- Inhibition of suppressor cells/factors and inactivation of ROS are also identified as key beneficial mechanisms.
Conclusions:
- BME holds potential as an adjunct therapy to improve outcomes for cancer patients treated with ICIs.
- Further clinical investigation is warranted to validate BME's efficacy in modulating the TME and enhancing anti-tumor immunity.
- Targeting the TME with specific thiols like BME could overcome current limitations in cancer immunotherapy.
More Related Videos
09:52A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
04:30Author Spotlight: Patient-Informed 3D Model for Studying Glioblastoma Invasion via Interstitial Fluid Flow
Published on: October 18, 2024
